Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10880.145 | 0.9193 | 0.8890 | 1.4751 | |
| AU565 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10880.145 | 0.9098 | 0.8758 | 1.4751 | |
| AU565 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10880.145 | 0.9856 | 0.9804 | 1.4751 | |
| AU565 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10880.145 | 1.0096 | 1.0130 | 1.4751 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 10581.145 | 0.9788 | 0.9532 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 10581.145 | 0.9450 | 0.8787 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 10581.145 | 0.9794 | 0.9545 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10581.145 | 0.9866 | 0.9704 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10581.145 | 1.0306 | 1.0678 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 10581.145 | 0.9691 | 0.9319 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 10581.145 | 0.9020 | 0.7844 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 10581.145 | 0.7075 | 0.3643 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 10581.145 | 0.7168 | 0.3840 | 0.9044 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 11854.145 | 0.9780 | 0.9619 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 11854.145 | 0.9177 | 0.8570 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 11854.145 | 1.0516 | 1.0889 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 11854.145 | 0.9774 | 0.9609 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 11854.145 | 1.0456 | 1.0785 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 11854.145 | 1.1054 | 1.1808 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 11854.145 | 0.8668 | 0.7678 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 11854.145 | 0.6955 | 0.4616 | 1.1581 | |
| BT-20 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 11854.145 | 0.7926 | 0.6363 | 1.1581 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12056.145 | 1.0175 | 1.0420 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12056.145 | 0.9392 | 0.8554 | 0.8365 | |
| BT-474 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12056.145 | 0.9452 | 0.8696 | 0.8365 |